Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nancy Thomas

Physician Assistant, Surgical Beaufort, SC Physician Assistant

NPI 1972906626 CMS profile 10596070

1055 Ribaut Rd, Beaufort, SC 29902

Open in the dashboard

General payments

$2,713

54 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nancy Thomas of Beaufort, SC is reported in the CMS Open Payments database as having received $2,713 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $237 1
2024 General $123 1
2023 General $359 18
2022 General $1,855 26
2021 General $139 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Thomas
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Nancy Thomas were reported at $237. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Nancy Thomas Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $139 $111 $36–$285 $132
2022 $1,855 $126 $44–$350 $149
2023 $359 $137 $47–$355 $160
2024 $123 $146 $49–$384 $164
2025 $237 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Teleflex LLC $1,740 20 payments
  2. Agiliti Surgical, Inc. $237 1 payment
  3. Boston Scientific Corporation $164 3 payments
  4. Astellas Pharma US Inc $133 5 payments
  5. Sumitomo Pharma America, Inc. $82 4 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $62 4 payments
  7. Myovant Sciences Inc. $60 3 payments
  8. Urovant Sciences Inc $33 2 payments
  9. AbbVie, Inc. $30 2 payments
  10. Axonics Modulation Technologies, Inc. $22 1 payment
  11. Other $151 9 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,338 48 payments
  2. Travel and Lodging $1,286 4 payments
  3. Education $89 2 payments
Products named General payments · program years 2021–2025
  1. UroLift System $1,465 9 payments
  2. UROLIFT $259 10 payments
  3. Sonablate HIFU $237 1 payment
  4. Koelis Trinity MRI/US Fusion $237 1 payment
  5. rezum Generator $123 1 payment
  6. GEMTESA $94 5 payments
  7. ORGOVYX $81 4 payments
  8. Nubeqa $62 4 payments
  9. Xofigo $62 4 payments
  10. MYRBETRIQ $45 3 payments
  11. Other $291 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,209

Median for Physician Assistant: 241

Drug cost

$384,179

Median for Physician Assistant: $4,110

Branded share of claims

24.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 309 $207,983
Gemtesa Vibegron Brand 136 $105,521
Dutasteride Generic 430 $18,591
Mirabegron Er Mirabegron Brand 25 $12,504
Tamsulosin Hcl Generic 449 $7,313
Tadalafil Generic 81 $4,568
Potassium Citrate Er Potassium Citrate Brand 43 $4,339
Solifenacin Succinate Generic 65 $3,858
Estradiol Generic 50 $3,693
Silodosin Generic 30 $3,232

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$106,029

Of which drugs: $11,390

Medicare patients

842

Average age 77

Services billed

2,675

318 women, 524 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 34%
Chronic kidney disease 29%
Ischemic heart disease 27%
Cancer 24%
Atrial fibrillation 21%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 15 81 $11,374

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record